# GNAS

Source: https://onco.cc/targets/gnas/  
OnCo record `gnas` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GNAS (Neuroendocrine secretory protein 55) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Pancreatic ductal adenocarcinoma, Breast cancer and 5 more.

## Summary

UniProt has no function text for O95467; HGNC names it "GNAS complex locus".

CIViC holds 17 clinical evidence items and 0 assertions across 5 variants, naming Trametinib, Palbociclib, Vemurafenib and Gefitinib and others. Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes genetic literature 0.30, affected pathway 0.61, literature 0.98, genetic association 0.03, somatic mutation 0.97, animal model 0.25). IntOGen calls it a driver in 12 cohorts (11 activating, 1 loss-of-function), covering Invasive Breast Carcinoma, Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, Lung Adenocarcinoma, Medulloblastoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: GNAS complex locus; Neuroendocrine secretory protein 55; NESP55; GNASXL; SCG6; SgVI; GNAS1
- Tags: cancer-genes-wave
- Symbol: GNAS
- Class: oncogene
- Biology: UniProt has no function text for O95467; HGNC names it "GNAS complex locus". Location: Cytoplasmic vesicle, secretory vesicle; Secreted (UniProt). Locus 20q13.32 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.67 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease; Pancreatic ductal adenocarcinoma: CIViC evidence names this disease; IntOGen driver in 5 cohorts (PAAD, PANCREAS); Breast cancer: CIViC evidence names this disease; IntOGen driver in 2 cohorts (BRCA); Bladder & urothelial cancer: CIViC evidence names this disease; Oesophageal cancer: CIViC evidence names this disease; IntOGen driver in 1 cohort (ESCA); Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 11 therapies; IntOGen calls it an activating (Act) driver in 11 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 17 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Pseudomyxoma Peritonei; Appendix Cancer; Follicular Thyroid Carcinoma; Histiocytosis-Lymphadenopathy Plus Syndrome.

## Sources

- HGNC HGNC:4392: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4392
- UniProt O95467: https://www.uniprot.org/uniprotkb/O95467/entry
- NCBI Gene 2778: https://www.ncbi.nlm.nih.gov/gene/2778
- Ensembl ENSG00000087460: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000087460

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/gnas.json